Faron Pharmaceuticals Oy (LSE:FARN) Other Long-Term Liabilities : £0.77 Mil (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Faron Pharmaceuticals Oy Other Long-Term Liabilities?

Faron Pharmaceuticals Oy's other long-term liabilities for the quarter that ended in Dec. 2023 was £0.77 Mil.

Faron Pharmaceuticals Oy's quarterly other long-term liabilities declined from Dec. 2022 (£0.88 Mil) to Jun. 2023 (£0.60 Mil) but then increased from Jun. 2023 (£0.60 Mil) to Dec. 2023 (£0.77 Mil).

Faron Pharmaceuticals Oy's annual other long-term liabilities increased from Dec. 2021 (£0.13 Mil) to Dec. 2022 (£0.88 Mil) but then declined from Dec. 2022 (£0.88 Mil) to Dec. 2023 (£0.77 Mil).

Faron Pharmaceuticals Oy Other Long-Term Liabilities Historical Data

The historical data trend for Faron Pharmaceuticals Oy's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Faron Pharmaceuticals Oy Other Long-Term Liabilities Chart

Faron Pharmaceuticals Oy Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Other Long-Term Liabilities

Get a 7-Day Free Trial

Faron Pharmaceuticals Oy Semi-Annual Data
	Dec13	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Other Long-Term Liabilities	Get a 7-Day Free Trial															-	-	-	-	-

Faron Pharmaceuticals Oy Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

Faron Pharmaceuticals Oy Other Long-Term Liabilities Related Terms

Thank you for viewing the detailed overview of Faron Pharmaceuticals Oy's Other Long-Term Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Faron Pharmaceuticals Oy (LSE:FARN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Faron Pharmaceuticals Oy (LSE:FARN) » Definitions » Other Long-Term Liabilities

Comparable Companies

Traded in Other Exchanges

FARON:Finland 4FR:Germany

Address

Joukahaisenkatu 6 B, Turku, FIN, 20520

Website

https://www.faron.com

Faron Pharmaceuticals Oy is a clinical-stage biopharmaceutical company developing novel treatments for medical conditions with unmet needs. The company has a pipeline based on the receptors involved in the regulation of immune response in oncology and organ damage. Clevegen (bexmarilimab), its investigative precision immunotherapy in phase I/II development as a novel macrophage checkpoint immunotherapy for patients with untreatable solid tumours, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation. Traumakine, the company's investigational intravenous interferon beta-1a is an anti-viral and anti-inflammatory agent, being tested in several Phase III studies around the world against COVID-19.

Faron Pharmaceuticals Oy (LSE:FARN) Headlines

No Headlines